Current Report Filing (8-k)
April 01 2019 - 5:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported):
April
1, 2019
AgeX
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
1-38519
|
82-1436829
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1010 Atlantic Avenue
Suite 102
Alameda, California 94501
|
(Address
of principal executive offices)
|
(510)
871-4190
(
Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company
⊠
If an
emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
⊠
Forward-Looking Statements
Any statements that are not historical fact (including, but not
limited to statements that contain words such as “may,” “will,”
“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)
should also be considered to be forward-looking statements. Additional
factors that could cause actual results to differ materially from the
results anticipated in these forward-looking statements are contained in
AgeX’s periodic reports filed with the SEC under the heading “Risk
Factors” and other filings that AgeX may make with the Securities and
Exchange Commission. Undue reliance should not be placed on these
forward-looking statements which speak only as of the date they are
made, and the facts and assumptions underlying these statements may
change. Except as required by law, AgeX disclaims any intent or
obligation to update these forward-looking statements.
References in this Report to “AgeX,” “we” or “us” refer to AgeX
Therapeutics, Inc.
The information in Item 2.02 and the accompanying Exhibit 99.1 shall
be deemed “furnished” and not “filed” under Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liability of that section, and shall not be incorporated
by reference into any filings made by OncoCyte under the Securities Act
of 1933, as amended, or the Exchange Act except as may be expressly set
forth by specific reference in such filing.
Item 2.02 - Results of Operations and Financial Condition
On April 1, 2019, AgeX issued a press release announcing its financial
results for the fourth quarter and fiscal year ended December 31, 2018.
A copy of the press release is attached as Exhibit 99.1, which, in its
entirety, is incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits.
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AGEX THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
Date:
|
April 1, 2019
|
|
By:
|
/s/ Russell Skibsted
|
|
|
|
|
Chief Financial Officer
|
|
2
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Sep 2023 to Sep 2024